SWTX - springworkstx.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics (SWTX) is scaling the expansion of Ogsiveo to capture the US oncology market. Experienced management has effectively transitioned the business into the commercial stage, while the absence of geopolitical barriers ensures research stability. The PEG ratio reflects the valuation dynamics relative to growth rates, with the metric currently standing at 0.00, helping to determine the asset's potential undervaluation.

SWTX: springworkstx.com Price/Earnings to Growth Multiple 07/04/2022 - 07/12/2025

Metric breakdowns and analytics for SpringWorks Therapeutics (SWTX)

- market value and analyst target forecast:
Price Rate Chart SpringWorks Therapeutics Inc.|SWTX - Consensus Target
- market capitalization statistics:
Market Value SpringWorks|SWTX - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share SpringWorks Therapeutics|SWTX - Company Net Assets|Market Cap to Book Value Multiple springworkstx.com|SWTX - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital SpringWorks Therapeutics|SWTX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital springworkstx.com|SWTX - Company Aggregate Debts|Debt to Net Assets SpringWorks|SWTX - Company Long-Term Debts|Short-Term Debt SpringWorks Therapeutics|Intermediate Liquidity Ratio springworkstx.com
- earnings and valuation multiples information:
SWTX - Net Profit|Expected Net Profit SpringWorks Therapeutics|SWTX - P/E Multiple|Price to Future Earnings Ratio SpringWorks Therapeutics, Inc|SWTX - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation SpringWorks|SWTX - Operating profit before deduction of amortization|Earnings per share for the last four quarters SpringWorks Therapeutics|SWTX - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months springworkstx.com|SWTX - Earnings growth in current year|Expected net earnings per share growth next year SpringWorks Therapeutics
General company analysis:SpringWorks Therapeutics
Signature product of springworkstx.com

Fundamental selection of promising assets is based on comparing market value and earnings growth, where a value below one signals an undervaluation of business potential. This ratio measures investment efficiency relative to earnings growth rates, which for SpringWorks Therapeutics (SWTX), as it monetizes innovative drugs for rare tumors, allows for an assessment of the company's capitalization fairness through changes in the PEG ratio.

Competing companies

Genmab AS (GMAB) - Price to Net Income Growth Ratio|Exelixis Corp - Price/Earnings to Growth Multiple|Nuvalent Therapeutics (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (ideayabio.com)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Pharma) - PEG Multiple|PEG Multiple Nurix Corp|Price/Earnings to Growth Ratio Tyra Biosciences, Inc. (TYRA)|VSTM (verastem.com) - Growth-Adjusted Payback Ratio|PEG Multiple GLUE (Monte Rosa Therapeutics, Inc.)|Price to Net Income Growth Ratio Cullinan Oncology|Immuneering Inc. - PEG Multiple|Price to Earnings Adjusted for Growth Rate C4 Therapeutics Corp|BDTX (Black Diamond) - Price/Earnings to Growth Multiple|RPTX: Company Value to Earnings Growth Ratio|PMVP (PMV Pharmaceuticals, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Karyopharm KPTI|PEG Multiple PPCB|Cyclacel - Growth-Adjusted P/E Ratio|Aadi Bioscience, Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ALRN|BPMC: Price/Earnings to Growth Multiple|GlycoMimetics, Inc. - Company Value to Earnings Growth Ratio